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Abstract
Introduction The 2014 American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society 
(HRS) guidelines recommend anticoagulation to reduce clot formation and the risk of thromboembolic events in patients 
with atrial fibrillation but does not specify guidelines for the elderly population. Direct oral anticoagulants (DOACs) are 
newer US FDA-approved alternatives to warfarin and include dabigatran, rivaroxaban, apixaban and edoxaban. The efficacy 
of DOACs is heavily researched, but few studies have evaluated their bleeding risk.
Objectives This systematic review and meta-analysis investigates which DOAC has the lowest bleeding risk in elderly 
patients with nonvalvular atrial fibrillation (NVAF).
Methods CINAHL and MEDLINE databases were searched using specific keywords, and 244 results were identified and 
screened. Inclusion criteria required a major bleeding event requiring hospitalization as an outcome and excluded patients 
with severe renal failure. Articles that met inclusion criteria were assessed for risk of bias using the Cochrane Tool to Assess 
Risk of Bias in Cohort Studies. Review Manager (version 5) was used to perform the random-effects model meta-analysis. 
Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. P < 0.05 was considered statistically significant.
Results Six articles met inclusion criteria and encompassed 446,042 patients in total. Apixaban and dabigatran had sta-
tistically significant risk reductions compared with warfarin, whereas rivaroxaban did not (HR 0.60 [95% CI 0.52–0.69], 
p < 0.00001; HR 0.79 [95% CI 0.70–0.90], p = 0.0005; HR 1.03 [95% CI 0.86–1.22], p = 0.77, respectively.) Data regarding 
edoxaban were limited and thus not included in the analysis.
Conclusion Apixaban and dabigatran have a significantly decreased major bleeding risk (40 and 21%, respectively) compared 
with warfarin. There was no statistical difference in bleeding risk between rivaroxaban and warfarin. Head-to-head prospec-
tive randomized controlled trials are required to assess the true bleeding risk of each DOAC.
 * Eric Nemec 
 nemece@sacredheart.edu
1 Sacred Heart University Physician Assistant Studies, 
Fairfield, CT, USA
2 Columbia University Medical Center, New York Presbyterian 
Hospital, New York, NY, USA
Key Points 
In patients aged > 65 years, apixaban and dabigatran have 
a significantly decreased major bleeding risk, 40 and 
21%, respectively, compared with warfarin.
In this population, there was no significant difference in 
bleeding risk between rivaroxaban and warfarin.
Providers should consider the relative bleeding risk 
when prescribing anticoagulants to older patients.
1 Introduction
Atrial fibrillation (AF) affects an estimated 2.7–6.1 million 
people in the USA, and the incidence is expected to rise as the 
population ages and life expectancies increase [1]. The preva-
lence of AF is higher in older and elderly populations, at about 
9% of people aged > 65 years and 2% of those aged < 65 years 
[7]. Current 2014 American Heart Association (AHA)/
American College of Cardiology (ACC)/Heart Rhythm Soci-
ety (HRS) guidelines recommend that clinicians control their 
patients’ heart rhythm or rate and prescribe an anticoagulant 
to reduce clot formation and risk of a thromboembolic event 
[1]. Further, the AHA reports that the risk of stroke in a patient 
with AF is four to five times higher than in an individual with-
out it, so it is imperative that patients in the general population 
are anticoagulated [7]. Anticoagulation of the elderly popu-
lation is less extensively studied, and the risks and safety of 
direct oral anticoagulants (DOACs) need further evaluation.
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Anticoagulant options for nonvalvular atrial fibril-
lation (NVAF) include warfarin and the newer DOACs, 
dabigatran, rivaroxaban, apixaban, and edoxaban [1, 2]. 
Warfarin is a vitamin K inhibitor that has been shown to 
effectively prevent stroke and reduce all-cause mortality in 
patients with NVAF [8]. However, it also requires regular 
monitoring of the international normalized ratio (INR) and 
dose adjustment to ensure the patient is within the narrow 
therapeutic range of 2.0–3.0, in the absence of a mechani-
cal valve. Because of this clinical burden and associated 
potential bleeding risk, the nonvitamin K inhibitors, also 
known as the aforementioned DOACs, were developed. 
ROCKET, RE-LY, ARISTOTLE, and ENGAGE AF-TIMI 
were landmark trials that resulted in US FDA approval of 
DOACs and provided pivotal data of the noninferiority and 
similar efficacy of rivaroxaban, dabigatran, apixaban, and 
edoxaban, respectively, as compared with warfarin [2–5].
Given the results of these large and well-known studies, 
the DOACs are now commonly prescribed to patients with 
NVAF because of their efficacy and safety as well as their 
lack of need for INR monitoring and dose adjustment. Of 
note, the current AHA/ACC/HRS guidelines for AF man-
agement were released in 2014 and do not include edoxa-
ban, which received FDA approval in 2015. This relatively 
recent approval means very little literature exists that com-
pares edoxaban with the other DOACs and warfarin.
Most DOAC studies have focused on the rate of throm-
boembolism and stroke prevention compared with warfa-
rin, but no head-to-head clinical trials have assessed the 
bleeding risk of each DOAC to determine best practice 
for prescribing to patients [9]. Additionally, no recom-
mendations are currently available regarding which DOAC 
to prescribe to patients, and the decision is often made 
according to provider preference, in conjunction with 
patient input and affordability.
While this a practical approach to prescribing, different 
DOACs may be superior in different patients with vari-
ous comorbidities and other contributing factors (such 
as age, lifestyle, compliance concerns, etc.). Of note, the 
prevalence of AF is 8–34% in patients with chronic kid-
ney disease undergoing hemodialysis, a disease that gener-
ally progresses with advanced age [10]. While NVAF is 
commonly encountered in severe renal failure, posing an 
increased risk of systemic thromboembolism, scant lit-
erature is available regarding DOAC recommendations. 
DOAC use for the prevention of thromboembolism or 
stroke in patients with NVAF and severe renal failure also 
requires dosing adjustment or may be contraindicated, 
depending on the DOAC and individual measurements of 
renal function. The use of DOACs in these patients also 
poses an increased bleeding risk; thus, drug choice, dos-
ing, and monitoring should be carefully considered before 
prescribing.
With the large majority of patients with NVAF being 
aged > 65 years, anticoagulation is common, but this pop-
ulation is also at increased risk of other associated com-
plications, including major bleeding [1, 11]. In addition to 
incidental intracranial or gastrointestinal bleeding in this 
population, the World Health Organization (WHO) reports 
an annual fall risk of 30% in community-dwelling people 
aged > 65 years [12]. This risk, combined with anticoagula-
tion in NVAF, imposes a risk of traumatic bleeding in addi-
tion to idiopathic bleeds in this population [13].
The ACC reported that a major hurdle to DOAC popular-
ity is their safety regarding bleeding risk and concern about 
a lack of reversal agents [14]. However, this should also be 
even less of a concern now, because, in addition to a reversal 
protocol for a warfarin-related bleed, all three major DOACs 
now have FDA-approved reversal agents [15, 16]. DOACs 
may be better suited anticoagulants for older patients with 
NVAF given the presence of reversal agents, simplicity 
in dosing, a lack of need for INR monitoring, as well as 
a potentially lower bleeding risk compared with warfarin. 
This review seeks to determine which DOAC has the lowest 
bleeding risk in patients with NVAF aged > 65 years.
2  Methodology
2.1  Data Sources and Search Strategy
Both CINAHL Complete and MEDLINE with Full Text 
were searched concomitantly using EBSCO Information 
Services on 12 July 2018 and 13 July 2018 using the fol-
lowing key terms: “dabigatran OR apixaban OR rivaroxa-
ban OR warfarin OR direct oral anticoagulant OR DOAC” 
AND “non-valvular atrial fibrillation OR atrial fibrilla-
tion” AND “bleed OR bleeding OR hemorrhage OR bleed 
risk OR bleeding risk OR hemorrhage risk”. All dupli-
cate articles were removed, and the following limits were 
applied: timeframe (2008–present), language (English), 
age of subjects (> 65 years), and peer-reviewed articles. 
A gray literature search was performed using the National 
Institute for Health and Care Excellence (NICE) database 
and the PROSPERO Clinical Trials Database using the 
same key terms. No additional studies were identified dur-
ing the gray literature search. Search results were exported 
from EBSCO into Covidence systematic review manager 
for screening and selection by two independent reviewers. 
Discrepancies were resolved via discussion.
2.2  Eligibility Criteria
Inclusion criteria were defined as follows: NVAF; 
includes apixaban, dabigatran and rivaroxaban; may or 
DOAC Bleeding Risk in NVAF Patients Aged > 65 Years
may not include warfarin; age > 65 years; retrospective 
propensity-matched cohort studies; and primary out-
come of major bleed or bleed risk. Exclusion criteria 
were defined as valvular or other causes of AF, wrong 
comparator (does not include apixaban, dabigatran, or 
rivaroxaban), studies focused on those aged < 65 years, 
review articles, and clinical trials. Clinical trials were 
excluded because a lack of method uniformity meant data 
compilation and making conclusions about outcomes 
were more difficult and because head-to-head DOAC 
clinical trials were scarce. Studies that used the same 
databases with overlapping patient data were evaluated 
to determine which were most inclusive of patients and 
had the largest timeframe.
The primary endpoint was bleed rate or risk with 
each DOAC compared with each other or with warfarin. 
A PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) statement flow diagram was 
used to report the review exclusion process and article 
selection.
2.3  Risk of Bias Evaluation
Risk of bias was evaluated in all included studies using the 
Cochrane Tool to Assess Risk of Bias in Cohort Studies. 
This tool assesses eight aspects, including subject selection, 
assessment of exposure, confidence in baseline, confounding 
variables, prognostic factors, outcome assessment, follow-
up, and co-intervention. The eight questions are assessed on 
a four-point scale: low risk, moderately low risk, moderately 
high risk, and high risk of bias. In this review, we included 
only studies assessed as having a low risk or moderately low 
risk of bias for all eight questions.
2.4  Meta‑Analysis
A meta-analysis was conducted using the five included 
studies that evaluated a major bleed. Review Manager 
(RevMan) software, version 5 (Copenhagen: the Nordic 
Cochrane Centre, The Cochrane Collaboration, 2008) was 
used to perform the meta-analysis following the recom-
mendations of the Cochrane Collaboration. Hazard ratios 
(HRs) and 95% confidence intervals (CIs) were calculated 
for dichotomous outcomes. The χ2 test and I2 statistics were 
calculated to determine heterogeneity, which was consid-
ered significant when the p value from χ2 was < 0.10 or 
when the I2 statistic was > 50%. A random-effects model 
was selected, and a funnel plot was created to evaluate 
publication bias. Statistical significance was accepted when 
p < 0.05.
3  Results
3.1  Study Selection
The specified search strategy identified 256 articles. Fol-
lowing import into Covidence, 12 duplicates were removed. 
In total, 244 studies were screened and 160 were excluded 
because they were irrelevant. Full-text assessment for eligi-
bility was performed on 84 studies, and 78 were excluded 
for reasons indicated in the PRISMA diagram (Fig. 1). Six 
studies were identified as propensity score-matched cohorts 
and were assessed for risk of bias (see Sect. 2.3). One study 
was identified as eligible but excluded because of a database 
overlap with another study, and the chosen study included 
a larger more expansive timeframe [17, 18]. All six studies 
had the lowest risk of bias for each of the eight questions and 
were included in this review.
3.2  Study Characteristics
All studies included in this review evaluated patients with 
NVAF and their bleeding risk while receiving one of the 
following anticoagulants: apixaban, dabigatran, rivaroxaban, 
or warfarin. Propensity score-matched cohorts were utilized 
in all studies to reduce the impact of confounders on the 
primary outcome. Four studies compared a DOAC with war-
farin, one study compared each DOAC with other DOACs, 
and the remaining study compared each DOAC with both 
warfarin and each DOAC [6, 18–22]. The follow-up period 
for studies ranged from 50 days to 2.5 years, with day 1 
Fig. 1  PRISMA Flow Diagram
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being the index date of prescription filled. The primary out-
come was a major or gastrointestinal bleed. The definition 
of a major bleed included bleed requiring hospitalization 
through to bleeding at major sites, including but not limited 
to intracranial, gastrointestinal, liver, splenic, and ocular. 
Patients were identified in databases using International 
Classification of Diseases, Ninth Edition (ICD-9) codes or 
variations of this coding system in other countries as well 
as billing and pharmacologic records. Sample sizes ranged 
from 38,622 to 186,132 patients. The origin of patient popu-
lations included the USA [6, 19, 20, 22], Japan [21], and 
Denmark [18]. Table 1 displays the specific characteristics 
of each study.
3.3  Risk of Bias
Based upon the Cochrane Tool to Assess Risk of Bias in 
Cohort Studies, the risk of bias was low for all six stud-
ies: they all used large, reliable data sources with access 
to insurance claims and hospital coding. All studies also 
utilized propensity score matching to reduce confounders 
and account for covariates that may impact the risk of bleed 
outcome.
3.4  Participant Characteristics
This review includes 446,042 patients diagnosed with 
NVAF and receiving anticoagulation for the first time or 
who had not been anticoagulated for at least 2 years before 
the start of each study [6, 18–22]. Most included studies 
reported patient characteristics within each propensity-
score matched cohort rather than as a summative depic-
tion, so this review provides the ranges of mean age and 
percentage of males included in each study, as shown in 
Table 2. The mean age of studies reported in this review 
ranges from 66.3 to 78.4 years, and the percentage of 
males ranges between 47.4 and 66.1%. Comorbidities 
were not reported in this review because those that would 
impact bleeding risk, such as renal disease, were excluded 
from included studies. Further, patients were propensity 
score matched based on similar demographic and clinical 
characteristics to best minimize confounding variables.
3.5  Major Bleed Risk Outcomes
All studies reported bleeding risk using HRs. Beyond major 
bleeds, two studies reported data on gastrointestinal bleed 
risk and one reported data on both gastrointestinal bleed and 
Table 1  Study characteristics
Major bleed includes bleeding at key sites, including but not limited to intracranial, gastrointestinal, liver, splenic and ocular hemorrhage
API apixaban, DAB dabigatran, RIV rivaroxaban, WAR warfarin
a Unless otherwise specified
Study Patients (N) Drugs evaluated Comparison group Median length of 
follow-up,  daysa
Data resource
Abraham et al. [6] 43,303 API, DAB, RIV API vs. DAB, API 89; DAB 120 OptumLabs Data Warehouse (contains commer-
cial and Medicare Advantage data)API vs. RIV API 89; RIV 106
DAB vs. RIV DAB 120; RIV 113
Amin et al. [19] 186,132 API, DAB, RIV API vs. WAR API 115; WAR 122 US Center of Medicare and Medicaid Services
DAB vs. WAR DAB 113; WAR 126
RIV vs. WAR RIV 130; WAR 120
Kohsaka et al. [21] 38,662 API, DAB, RIV API vs. WAR API 82; WAR 50 Medical Data Vision Company Japanese Data-
baseDAB vs. WAR DAB 154; WAR 148
RIV vs. WAR RIV 99; WAR 67
Li et al. [22] 76,940 API API vs. WAR API 119; WAR 122 US Truven MarketScan, PharMetrics, Optum 
and Humana Databases
Lip et al. [20] 45,361 API, DAB, RIV API vs. WAR API 96; WAR 100 US Truven MarketScan Commercial Claims and 
Encounter and Medicare Supplemental and 
Coordination of Benefits Databases
DAB vs. WAR DAB 100; WAR 97
RIV vs. WAR RIV 113; WAR 100
API vs. DAB API 93; DAB 103
API vs. RIV API 95; RIV 116
DAB vs. RIV DAB 100; RIV 111
Nielsen et al. [18] 55,644 API, DAB, RIV API vs. WAR 2.5 years for all Danish National Prescription Registry, Danish 
National Patient Register, Danish Civil Regis-
tration System
DAB vs. WAR 
RIV vs. WAR 
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intracranial bleed risk [6, 19]. When comparing each DOAC 
with warfarin, warfarin was considered the reference stand-
ard. Only one study reported data on major bleed risk when 
comparing DOACs with each other and with warfarin [20].
3.5.1  Apixaban
Apixaban appears to have the lowest major bleeding risk, 
with four studies reporting between 21% (HR 0.79 [95% CI 
0.65–0.96]) and 49% (HR 0.51 [95% CI 0.44-0.58]) com-
pared with warfarin, shown in Table 3 [18–21]. Further, all 
four studies that evaluated major bleed risk reported a lower 
risk with apixaban than with dabigatran and rivaroxaban 
compared with warfarin.
Following meta-analysis, apixaban had a statistically sig-
nificant 40% reduction in major bleeding risk (HR 0.60 [95% 
CI 0.52–0.69] p < 0.00001), as shown in Table 4. The dataset 
is also considered heterogenous, with a χ2 of 12.55 and I2 
of 68%. Further, the heterogeneity and low publication bias 
of the studies included in the meta-analysis of apixaban is 
evidenced by the funnel plot in Fig. 2. 
3.5.2  Dabigatran
Four of the six included studies also suggested that dabi-
gatran has a statistically significant lower risk of major bleed 
than warfarin, with the risk reduction ranging from 21% 
(HR 0.79 [95% CI 0.69–0.91]) to 38% (HR 0.62 [95% CI 
0.43–0.90]), shown in Table 5. While these rates are similar 
to those reported in this review for apixaban, it is important 
to note that the majority of included studies reported statis-
tically significant and greater risk reduction with apixaban 
than with warfarin. Further, when bleeding risk was assessed 
between apixaban and dabigatran, dabigatran had a 41% 
greater risk than apixaban for a major bleed (HR 1.41 [95% 
CI 0.93–2.14]) but did not reach statistical significance [20].
Table 2  Participant characteristics
SD standard deviation
a Ranges reported due to differences between propensity score-
matched cohorts
b Reported as median
Study Age, mean ± SD Sex (% male)
Abraham et al. [6] 69.2 ± 11.6 to 72.3 ± 11.1a 53.9–59.7b
Amin et al. [19] 77.1 ± 7.3 to 78.4 ± 7.4a 47.4–51.0b
Kohsaka et al. [21] 73.1 ± 9.9 to 77.7 ± 10.0a 58.9–66.1b
Li et al. [22] 70.9 ± 11.9–12.0a 59.7–59.8b
Lip et al. [20] 66.3 ± 12.3–70.1 ± 12.0a 60.9–65.0b
Nielsen et al. [18] 73.9 ± 12.7 55.1%
Table 3  Apixaban bleeding risk
Data are presented as hazard ratio (95% confidence interval)
NA data not available
*p < 0.05
Apixaban vs. Major bleed Gastrointestinal bleed Intracranial bleed








Dabigatran NA 0.39*(0.27–0.58) [6] NA
Rivaroxaban NA 0.33*(0.22–0.49) [6] NA








Heterogeneity: Tau² = 0.02; Chi² = 12.55, df = 4 (P = 0.01); I² = 68%



























Hazard Ratio Hazard Ratio
IV, Random, 95% CI
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Favours Apixaban Favours Warfarin
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Meta-analysis of the included studies determined that 
dabigatran has a 21% reduction in major bleeding risk 
compared with warfarin (HR 0.79 [95% CI 0.70–0.90], 
p = 0.0005), shown in Table 6. The included studies are also 
considered moderately heterogeneous, with a χ2 of 5.08 and 
an I2 of 41%. Further, the funnel plot for included dabigatran 
studies exhibits low publication bias, as evidenced by Fig. 3. 
3.5.3  Rivaroxaban
The major bleeding risk with rivaroxaban was comparable to 
that with warfarin in three studies, shown in Table 7 [18, 20]. 
In addition, one study showed a statistically significant risk 
reduction of 31%, and another showed a 17% significantly 
increased risk of major bleed compared with warfarin (HR 
0.69 [95% CI 0.51–0.93]), HR 1.17 [95% CI 1.10–1.26], 
respectively) [19, 21]. When compared with apixaban, rivar-
oxaban incurred an 82% increased risk of bleeding (HR 1.82 
[95% CI 1.36–2.43]) [20]. In comparison with dabigatran, 
major bleeding risk with rivaroxaban was not statistically 
significantly different [20].
Meta-analysis indicated that the bleeding risk with rivar-
oxaban was comparable to that with warfarin (HR 1.03 [95% 
CI 0.86–1.22], p = 0.77), shown in Table 8. These results are 
drawn from a heterogeneous dataset with a χ2 of 14.62 and 
I2 of 79%. Further, the funnel plot displayed in Fig. 4 pro-
vides evidence for a low publication bias and heterogeneity 
of included studies. 
3.6  Gastrointestinal Bleeding Risk
As displayed in Tables 3, 5, and 7, the risk of a gastroin-
testinal bleed while taking apixaban was lower by 37% 
(HR 0.63 [95% CI 0.52–0.76]) and 38% (HR 0.62 [95% CI 
0.55–0.71]), both statistically significant compared with 








Fig. 2  Apixaban Funnel Plot
Table 5  Dabigatran bleeding 
risk
Data are presented as hazard ratio (95% confidence interval)
NA data not available
*p < 0.05
Dabigatran vs. Major bleed Gastrointestinal bleed Intracranial bleed




1.02 (0.85–1.23) [19] 0.54* (0.35–0.82) [19]
Apixaban 1.41 (0.93–2.14) [20] NA NA
Rivaroxaban 1.05 (0.74–1.49) [20] NA NA







Heterogeneity: Tau² = 0.01; Chi² = 5.08, df = 3 (P = 0.17); I² = 41%
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warfarin [19, 22]. The risk with apixaban was 61% (HR 0.39 
[95% CI 0.27–0.58]) lower than with dabigatran and 67% 
(HR 0.33 [95% CI 0.22–0.49]) lower than with rivaroxaban 
[6]. When compared with warfarin, dabigatran and rivar-
oxaban incurred an increased risk, but only the risk with 
rivaroxaban reached statistical significance (HR 1.35 [95% 
CI 1.23–1.48]) [19]. No statistically significant difference 
in risk was found when rivaroxaban and dabigatran were 
compared with each other [6].
3.7  Intracranial Bleeding Risk
The risk of intracranial bleeding reduced for all three 
DOACs compared with warfarin, shown in Tables 3, 5, and 
7 [19]. None of the included studies compared intracranial 
bleeding risk between DOACs or specific intracranial bleed-
ing outcomes. When compared with warfarin, dabigatran 
displayed the largest reduction in intracranial bleeding risk, 
with a 53% reduction reported in one study (HR 0.54 [95% 
CI 0.35–0.82]) [19]. Apixaban displayed a 62% (HR 0.38 
[95% CI 0.25–0.56]) and 36% (HR 0.64 [95% CI 0.50–0.80]) 
intracranial bleeding risk reduction in two studies [19, 22].
3.8  Major Bleeding Risk in Patients Aged > 80 Years
It is important to understand the impact of DOACs on 
patients aged > 80 years, because these patients are more 
likely to need close monitoring because of their increased 
fall risk and to require dose adjustment because of renal 
failure. Only one study reported data specific to patients 
aged > 80 years (Table 9) [18]. All DOACs were compared 
with warfarin; while apixaban was the only DOAC with a 
major bleeding risk reduction (15%), it did not reach sta-
tistical significance. The analysis of rivaroxaban did show 








Fig. 3  Dabigatran Funnel Plot
Table 7  Rivaroxaban bleeding 
risk
Data are presented as hazard ratio (95% confidence interval)
NA data not available
*p < 0.05
Rivaroxaban vs. Major bleed Gastrointestinal bleed Intracranial bleed




1.35* (1.23–1.48) [19] 0.71* (0.59–0.87) [19]
Apixaban 1.82* (1.36–2.43) [20] NA NA
Dabigatran 1.05 (0.74–1.49) [20] 1.20 (1.00–1.45) [6] NA







Heterogeneity: Tau² = 0.02; Chi² = 14.62, df = 3 (P = 0.002); I² = 79%
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statistical significance, with a reported 28% increased risk 
of major bleed in patients aged > 80 years (HR 1.28 [95% 
CI 1.00–1.63]) [18]. This study also reported 2.5 years 
of follow-up and included almost 20,000 individuals 
aged > 80 years, all of whom were prescribed a “low-dose” 
DOAC. This represents a robust study from which strong 
conclusions regarding safety can be drawn.
3.9  Cost for Drugs and Reversal Agents
Costs for a 28-day supply of a DOAC, and the costs 
for reversal agents, are higher than those for warfarin 
(Table 10). The total monthly cost is $US448.56–469.28 
for all DOACs [23]. Warfarin is significantly less expen-
sive, with a range of $US17.08–27.16 per 28  days of 
medication, excluding INR testing and other associated 
expenses [23]. The reversal agent, andexanet alfa, is newer 
to the market and approved for reversal of apixaban and 
rivaroxaban at a cost of $US3300 for every 100 mg [15, 
23]. The price of andexanet alfa greatly contrasts with that 
for idariucizumab, the reversal agent for dabigatran, which 
costs $US42.00 for every 2.5 g/50 mL vial. Total dos-
ing for reversal agents often depends upon variables such 
as dosing of the anticoagulant or INR when a patient is 
receiving warfarin. This often requires adjustment of the 
total reversal agent dose and thus can alter the overall cost.
4  Discussion
4.1  Summary of Main Findings
Apixaban, dabigatran, and rivaroxaban have already been 
shown to be noninferior to warfarin when considering 
thromboembolic event risk [3–5]. Bleeding risk is an 
important consideration when prescribing anticoagulants 
to patients because the incidence of NVAF increases with 
advanced age. Beyond the standard bleeding risk (gas-
trointestinal, intracranial, etc.) associated with increased 
age, older patients are also at a greater risk for falls and 
therefore traumatic bleeding events [24]. Current studies 
recommend that providers continue to prescribe antico-
agulants to patients with NVAF despite their fall risk [24, 
25]. While DOACs are still recommended in the elderly, 








Fig. 4  Rivaroxaban Funnel Plot
Table 9  Direct oral 
anticoagulant major bleeding 
risk compared with warfarin 
by age
Data are presented as hazard ratio (95% confidence interval)
NA data not available
*p < 0.05
Apixaban Dabigatran Rivaroxaban
> 80 years 0.85 (0.67–1.08) [18] 1.01 (0.84–1.20) [18] 1.28 (1.00–1.63) [18]
Table 10  Direct oral anticoagulant and reversal agent standard dosing and cost
All pricing data are from uptodate.com and presented in $US [23]
BID twice daily, INR international normalized ratio, IV intravenous, OD once daily, PCC prothrombin complex concentrate
a Dosing dependent upon last apixaban or rivaroxaban dose amount
b Dosing dependent upon INR
Drug Dose Cost per 28 days Reversal agent Total dose Reversal agent cost
Apixaban 5 mg BID 469.28 Andexanet alfa 880–1760 mg  IVa 3300.00 per 100 mg
Dabigatran 150 mg BID 448.56 Idarucizumab 5 g IV 42.00 per 2.5 g/50 mL
Rivaroxaban 20 mg OD 469.28 Andexanet alfa 880–1760 mg  IVa 3300.00 per 100 mg
Warfarin 2–10  mgb OD 17.08–27.16 Vitamin K and PCC 2.5–10  mgb and 50 U/kg 66.99 per 5 mg and 2.77 per unit
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it is important to recognize the exclusion of severe renal 
failure from this review and analysis. Current strategies 
in the elderly population overall require an individualized 
approach that considers all comorbidities before DOAC 
selection and dose adjustment where necessary [26].
Meta-analysis indicates that apixaban and dabigatran 
have a significantly lower major bleeding risk, 40 and 27%, 
respectively, than warfarin. Thus, in terms of major bleed-
ing events, apixaban and dabigatran appear to possess a 
better safety profile for patients with NVAF aged > 65 years 
than warfarin [6, 18–22]. However, meta-analysis indicates 
that rivaroxaban has comparable major bleeding risk, and 
some studies reported an increased risk of major bleeding 
compared with warfarin [18–20]. When directly comparing 
DOACs, the included studies indicated that apixaban had 
the lowest risk of major bleeding, followed by dabigatran, 
and finally rivaroxaban and warfarin [20].
Gastrointestinal and intracranial bleeds are also more 
likely among the elderly. Two studies reported that apixa-
ban also had the lowest risk of gastrointestinal bleed com-
pared with warfarin, dabigatran, and rivaroxaban [6, 19]. 
Dabigatran posed the lowest risk of intracranial bleed 
[19]. Apixaban and dabigatran both had overall significant 
reductions in both gastrointestinal and intracranial bleeds, 
whereas rivaroxaban did not [6, 19, 22]. Only one study 
reported data for patients aged < 80 years, and none of the 
DOACs showed significant bleeding risk reduction or an 
increase compared with warfarin [18].
The evidence provided by the included studies is 
strengthened by their robust sample size, reliable data 
sources, and propensity score-matched cohorts. All 
data sources were based on insurance claims collected 
and compiled by either federal or commercial insurance 
or medical entities. Propensity score-matched cohorts 
matched patients by their socioeconomic, demographic, 
and clinical characteristics to best compare the most simi-
lar patients. This method also helps reduce the impact of 
confounders on the outcome, in this case bleeding risk.
4.2  Strengths and Limitations
All of the included studies were retrospective in design and 
thus are limited to the strength of record keeping and data 
collection. Also common with retrospective studies evalu-
ating medications, physician prescribing methods are done 
in a nonrandomized manner. In these studies, medication 
compliance cannot be directly assessed, only implied based 
on claims data and pharmacy records. In addition, none of 
the included studies accounted for warfarin dose adjustment 
and over-the-counter aspirin use, but both could contribute 
to overall bleeding risk. Bleeding could have also occurred 
beyond the follow-up periods of the included studies, so con-
clusions cannot be drawn about the longer-term bleeding risk.
All six studies are considered observational cohorts and 
thus only associations are assessed and causal relationships 
cannot be inferred. All six studies use propensity score-
matched cohorts, so while confounders may still exist, their 
impact is minimized.
One study strictly used Medicare data, so these findings 
may or may not be generalizable to other elderly popula-
tions, such as those with commercial or veteran benefits, as 
they may represent different socioeconomic populations with 
different comorbidities [19]. To alleviate this, this review 
also included a study using a database from a US commer-
cially insured older population [20]. It is also important to 
note that where ICD-9 codes are used to identify the NVAF 
population in databases, differentiation between permanent, 
persistent, and paroxysmal AF cannot be made. These spe-
cific subsets of NVAF may have different bleeding risks that 
cannot be assessed using this method.
Finally, the external validity of the included studies is 
strong, as the setting, study characteristics, and design were 
all relevant and appropriate. All studies possessed a very 
robust sample size and used large, reliable databases from 
which conclusions can be drawn. Further, the risk of bias 
was assessed using the Cochrane Tool to Assess Risk of 
Bias in Cohort Studies and all studies had a low risk of bias.
4.3  Review Limitations and Weaknesses
The outcomes of this review may be limited by the num-
ber of databases searched and the possibility of incomplete 
retrieval of relevant literature. Because of this, gray lit-
erature searches were also performed. Further, this review 
only included propensity score-matched studies in an effort 
to ensure a low risk of bias in reporting, but the methods 
employed may also limit the generalizability of the findings. 
This study design was selected because of the reproducibility 
and the low number of randomized controlled trials during 
preliminary searches. The exclusion of patients with severe 
renal failure also does not allow for generalization of study 
conclusions to this population commonly affected by NVAF.
This review is strengthened by the meta-analysis per-
formed and findings that are consistent with those of the 
review. Further, funnel plots of each DOAC compared with 
warfarin display heterogeneity and low publication bias 
influencing the outcome. Two reviewers also provided inde-
pendent review to minimize the selection bias of included 
studies.
5  Conclusion
This review supports the use of apixaban or dabigatran over 
rivaroxaban or warfarin because of their lower bleeding 
risk, as evidenced by a literature review and meta-analysis. 
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Providers must undertake significant consideration when 
prescribing DOACs in order to reduce the risk of thrombo-
embolism appropriately but also factor in the bleeding risk, 
as it can be equally fatal. It is imperative to have conversa-
tions with patients regarding anticoagulant options and risks, 
because while warfarin has lower direct costs (excluding 
INR monitoring and associated costs), it may pose increased 
bleeding risk and requires regular dosing adjustment based 
upon INR results. The DOACs in patients with normal renal 
function require less frequent monitoring and have a more 
manageable dosing schedule, but their cost may be sig-
nificantly higher for the patient dependent upon insurance 
coverage. Adding to the considerable cost, reversal agents 
for apixaban and rivaroxaban are extremely expensive com-
pared with idarucizumab for dabigatran or vitamin K and 
prothrombin complex concentrate for warfarin [23]. As a 
team, the provider and patient must weigh the costs, benefits, 
risks, and lifestyle changes before selecting an anticoagulant 
to best ensure safety and compliance. The overall burden and 
cost to a patient may be lower with apixaban or dabigatran 
given the lower bleeding risk and need for fewer office visits 
and monitoring compared with warfarin.
Future research should consider a prospective randomized 
controlled head-to-head trial of DOACs and include the 
newest to the market, edoxaban. A study should evaluate 
both efficacy (thromboembolism risk) and safety (bleeding 
risk) to best determine superiority of a specific DOAC. This 
future research should also better stratify demographics, 
such as age and ethnicity, as well as comorbidities (includ-
ing but not limited to renal failure, dementia, other hyperco-
agulable diseases) to enhance the generalizability of results 
to more specific populations. Additional studies comparing 
the costs associated with each DOAC and warfarin, includ-
ing prescriptions, monitoring, and hospitalizations are also 
needed to assess the potential fiscal burden on the patient 
and the healthcare system.
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